Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α - Concepedia

Concepedia

Publication | Closed Access

Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α

120

Citations

30

References

2002

Year

K. Lea Sewell, Richard S. Geary, Brenda F. Baker, Josephine Glover, Timothy Mant, Rosie Z. Yu, Joseph A. Tami, F. Andrew Dorr

Journal of Pharmacology and Experimental Therapeutics

References

	Year	Citations

Page 1